001     154696
005     20240229123109.0
024 7 _ |a 10.1002/mds.28039
|2 doi
024 7 _ |a pmid:32357270
|2 pmid
024 7 _ |a 0885-3185
|2 ISSN
024 7 _ |a 1531-8257
|2 ISSN
024 7 _ |a altmetric:81186441
|2 altmetric
037 _ _ |a DKFZ-2020-00954
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Peters, Susan
|0 0000-0001-5662-1971
|b 0
245 _ _ |a Alcohol Consumption and Risk of Parkinson's Disease: Data from a Large Prospective European Cohort.
260 _ _ |a New York, NY
|c 2020
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1598872457_21558
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2020 Jul;35(7):1258-1263
520 _ _ |a Parkinson's disease (PD) etiology is not well understood. Reported inverse associations with smoking and coffee consumption prompted the investigation of alcohol consumption as a risk factor, for which evidence is inconclusive.To assess the associations between alcohol consumption and PD risk.Within NeuroEPIC4PD, a prospective European population-based cohort, 694 incident PD cases were ascertained from 209,998 PD-free participants. Average alcohol consumption at different time points was self-reported at recruitment. Cox regression hazard ratios were estimated for alcohol consumption and PD occurrence.No associations between baseline or lifetime total alcohol consumption and PD risk were observed. Men with moderate lifetime consumption (5-29.9 g/day) were at ~50% higher risk compared with light consumption (0.1-4.9 g/day), but no linear exposure-response trend was observed. Analyses by beverage type also revealed no associations with PD.Our data reinforce previous findings from prospective studies showing no association between alcohol consumption and PD risk. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Gallo, Valentina
|0 0000-0002-1268-8629
|b 1
700 1 _ |a Vineis, Paolo
|b 2
700 1 _ |a Middleton, Lefkos T
|b 3
700 1 _ |a Forsgren, Lars
|b 4
700 1 _ |a Sacerdote, Carlotta
|b 5
700 1 _ |a Sieri, Sabina
|b 6
700 1 _ |a Kyrozis, Andreas
|b 7
700 1 _ |a Chirlaque, María-Dolores
|b 8
700 1 _ |a Zamora-Ros, Raul
|b 9
700 1 _ |a Hansson, Oskar
|b 10
700 1 _ |a Petersson, Jesper
|b 11
700 1 _ |a Katzke, Verena
|0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
|b 12
|u dkfz
700 1 _ |a Kühn, Tilman
|0 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
|b 13
|u dkfz
700 1 _ |a Mokoroa, Olatz
|b 14
700 1 _ |a Masala, Giovanna
|b 15
700 1 _ |a Ardanaz, Eva
|b 16
700 1 _ |a Panico, Salvatore
|b 17
700 1 _ |a Bergmann, Manuela M
|b 18
700 1 _ |a Key, Timothy J
|b 19
700 1 _ |a Weiderpass, Elisabete
|b 20
700 1 _ |a Ferrari, Pietro
|b 21
700 1 _ |a Vermeulen, Roel
|b 22
773 _ _ |a 10.1002/mds.28039
|g p. mds.28039
|0 PERI:(DE-600)2041249-6
|n 7
|p 1258-1263
|t Movement disorders
|v 35
|y 2020
|x 1531-8257
909 C O |o oai:inrepo02.dkfz.de:154696
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2020
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOVEMENT DISORD : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b MOVEMENT DISORD : 2017
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21